Certis Oncology Solutions

Executive Summary

Certis Oncology Solutions is a San Diego-based biotechnology company that combines artificial intelligence with patient-derived cancer models to enhance translational data for oncology drug development. Founded in 2015, its flagship platform, Certis Oncology Intelligence®, aims to de-risk and accelerate the path of new therapies from lab to clinic by providing more predictive and clinically relevant insights compared to traditional preclinical models. Operating at the intersection of oncology and diagnostics, the company offers a unique value proposition to pharmaceutical partners seeking to improve the success rate of cancer drug candidates. As a private company with no disclosed funding or pipeline details, Certis Oncology Solutions remains in a growth phase, likely seeking to expand its partnerships and secure additional capital. Its technology addresses a critical gap in oncology R&D, where conventional models often fail to predict human responses. If the company can validate its platform through peer-reviewed studies and strategic collaborations, it could become a key player in the precision oncology space. However, without public financial data or regulatory milestones, its near-term visibility is limited.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a top-20 pharmaceutical company70% success
• Q4 2026Series B funding round led by prominent healthcare investors60% success
• Q2 2026Publication of a peer-reviewed validation study for Certis Oncology Intelligence® platform80% success